SomaLogic boosts sales, trims losses

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public last year in a merger with a special purpose acquisition company, grew its revenues by more than 20% in the first quarter of 2022 and cut its losses by more than half.

Sales for the most recent period were $23.0 million, a 21.8% increase from $18.9 million in the corresponding period of 2021.

SomaLogic posted a net loss of $4 million, or 2 cents per share, compared to a loss of $9.5 million or 8 cents per share in the first quarter of 2021.

SomaLogic, which develops platforms to…